1
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
1 of 3
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- 37 College StreetNew Haven, CT 06510
Thomas Prebet, MD, PhD
Medical Oncology, Hematology & Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Titles
- Associate Professor Adjunct
Education & Training
- Post-Doctoral FellowJohns Hopkins University (2010)
- PhDCentre de Recherche en Cancerologie (2009)
- MSClaude Bernard University (2005)
- ResidentUniversity Hospitals of Lyon (2004)
- MDMontpellier University (2000)
Languages Spoken
- English
- Français (French)
Additional Information
Honors & Recognitions
- Award from association Laurette Fugain: Société Française d’hématologie (2012)
- Award from French transfusion medicine society: association recherche transfusion/ société Française de Transfusion Sanguine (2011)
Professional Service
- Inpatient Re-Organization Project Steering Committee (2019 - Present): Member
- Inpatient Hospitalist Sub-Committee (2019 - Present): Co-Chair
- Elderly French CLL Intergroup Study (2019 - Present): Member
- French National AML Trial (2019 - Present): Chair
- French National AML Trial (2018 - 2019): Member
- Smilow Telehealth Initiatives (2018 - Present): Participant
- Yale Affiliated Hospital Program (2018 - Present): Lecturer
- Yale Biological Safety Committee, Human Gene Therapy Subcommittee (2018 - Present): Member
- Yale Cancer Center Chief Medical Officer Search Committee (2018 - Present): Member
- Yale Cancer Center Clinical Trial Office Search Committee (2018 - Present): Member
Publications
- Shimony S, Murdock H, Keating J, Tsai H, Sasi A, Gibson C, Faderl S, Wagner A, Dronamraju N, Lin T, Prebet T, Cortes J, Uy G, Lancet J, Reilly C, Neuberg D, Stone R, Lindsley R. CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial. Blood Advances 2026, 10: 2854-2864. PMID: 41628350, PMCID: PMC13133533, DOI: 10.1182/bloodadvances.2025019378.
- Voso M, de Botton S, Pfeilstöcker M, Alvarez A, Wang K, See W, Guerrero M, de Menezes D, Petrlik E, Prebet T, Roboz G. Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia‐related changes: Post hoc analysis of the QUAZAR AML‐001 trial. British Journal Of Haematology 2025, 208: 746-751. PMID: 41387169, DOI: 10.1111/bjh.70272.
- Boyiadzis M, Wei A, Paiva B, Freeman S, Kaspers G, Chyla B, Hersey S, Patel R, Maloney B, Zumofen M, Van Hoef M, Wulff B, Obourn V, Patel S, de Menezes D, Shi Q, Bengoudifa B, Dimier N, Prior T, Roboz G, Prebet T. Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium. Cancer 2025, 131: e35960. PMID: 40576165, PMCID: PMC12203635, DOI: 10.1002/cncr.35960.
- Leber B, Ruiz M, Elgendy H, Pettersson F, Prebet T, Vigil C, Parikh R, Korgaonkar S, Bello F, Davis K, Gaugler L, Strocchia M, Sieluk J, Li Y, Schuh A. Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Cancer 2025, 131: e35845. PMID: 40233158, DOI: 10.1002/cncr.35845.
- Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma 2024, 66: 479-487. PMID: 39606887, DOI: 10.1080/10428194.2024.2425792.
- Poloni A, Raaschou-Jensen K, Mohedo F, Paolini S, Oliva E, Buccisano F, Vasconcelos A, Kim I, Makwana A, Bernasconi D, Rosettani B, Prebet T, Santini V. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e131-e142. PMID: 39516085, DOI: 10.1016/j.clml.2024.10.007.
- Borate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study. Advances In Therapy 2024, 41: 4049-4064. PMID: 39240504, PMCID: PMC11480148, DOI: 10.1007/s12325-024-02947-1.
- Della Porta M, Garcia-Manero G, Santini V, Zeidan A, Komrokji R, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. The Lancet Haematology 2024, 11: e646-e658. PMID: 39038479, DOI: 10.1016/s2352-3026(24)00203-5.
- Montesinos P, Fathi A, de Botton S, Stein E, Zeidan A, Zhu Y, Prebet T, Vigil C, Bluemmert I, Yu X, DiNardo C. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Advances 2024, 8: 2509-2519. PMID: 38507688, PMCID: PMC11131052, DOI: 10.1182/bloodadvances.2023011914.
- Risueño A, See W, Bluemmert I, de Botton S, DiNardo C, Fathi A, Schuh A, Montesinos P, Vyas P, Prebet T, Gandhi A, Hasan M. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leukemia Research 2024, 140: 107497. PMID: 38564986, DOI: 10.1016/j.leukres.2024.107497.
- Mims A, Xie Z, Vasconcelos A, Strocchia M, Heydendael W, Chevli M, Rotter D, Potluri R, Prebet T, Sieluk J. Corrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 203-204. DOI: 10.1016/j.clml.2023.11.010.
- Watts J, Baer M, Yang J, Prebet T, Lee S, Schiller G, Dinner S, Pigneux A, Montesinos P, Wang E, Seiter K, Wei A, De Botton S, Arnan M, Donnellan W, Schwarer A, Récher C, Jonas B, Ferrell P, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard S, Brevard J, Henrick P, Mohamed H, Cortes J. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. The Lancet Haematology 2022, 10: e46-e58. PMID: 36370742, PMCID: PMC12250719, DOI: 10.1016/s2352-3026(22)00292-7.
- Pollyea D, Bixby D, Perl A, Bhatt V, Altman J, Appelbaum F, de Lima M, Fathi A, Foran J, Gojo I, Hall A, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin M, Mims A, Neff J, Nejati R, Olin R, Percival M, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami P, Stone R, Strickland S, Sweet K, Vachhani P, Wieduwilt M, Gregory K, Ogba N, Tallman M. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 16-27. PMID: 33406488, DOI: 10.6004/jnccn.2021.0002.
- Tallman M, Wang E, Altman J, Appelbaum F, Bhatt V, Bixby D, Coutre S, De Lima M, Fathi A, Fiorella M, Foran J, Hall A, Jacoby M, Lancet J, LeBlanc T, Mannis G, Marcucci G, Martin M, Mims A, O'Donnell M, Olin R, Peker D, Perl A, Pollyea D, Pratz K, Prebet T, Ravandi F, Shami P, Stone R, Strickland S, Wieduwilt M, Gregory K, Hammond L, Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 721-749. PMID: 31200351, DOI: 10.6004/jnccn.2019.0028.
- Fenaux G, Ades L, Fontenay M, Raynaud S, Eclache V, Rose C, Guerci-Bresler A, Gyan E, Robin M, Prebet T, Itzykson R, Cluzeau T, Natarajan-Amé S, Stamatoullas A, Wattel E, Park S, Beyne Rauzy O, Solary E, Bordessoule D, Isnard F, Quesnel B, Yakoub Agha I, Toma A, Thépot S, Braun T, Gardin C, Chèze S, Delaunay J, Dimicoli S, Kosmider O, Renneville A, Preudhomme C, Chermat F, Vey N, Dreyfus F. French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. Hématologie 2015, 21: 28-45. DOI: 10.1684/hma.2015.0979.
Departments and Programs
Locations
1
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
1 of 3
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- 37 College StreetNew Haven, CT 06510
Titles
- Associate Professor Adjunct
Education & Training
- Post-Doctoral FellowJohns Hopkins University (2010)
- PhDCentre de Recherche en Cancerologie (2009)
- MSClaude Bernard University (2005)
- ResidentUniversity Hospitals of Lyon (2004)
- MDMontpellier University (2000)
Languages Spoken
- English
- Français (French)
Additional Information
Honors & Recognitions
- Award from association Laurette Fugain: Société Française d’hématologie (2012)
- Award from French transfusion medicine society: association recherche transfusion/ société Française de Transfusion Sanguine (2011)
Professional Service
- Inpatient Re-Organization Project Steering Committee (2019 - Present): Member
- Inpatient Hospitalist Sub-Committee (2019 - Present): Co-Chair
- Elderly French CLL Intergroup Study (2019 - Present): Member
- French National AML Trial (2019 - Present): Chair
- French National AML Trial (2018 - 2019): Member
- Smilow Telehealth Initiatives (2018 - Present): Participant
- Yale Affiliated Hospital Program (2018 - Present): Lecturer
- Yale Biological Safety Committee, Human Gene Therapy Subcommittee (2018 - Present): Member
- Yale Cancer Center Chief Medical Officer Search Committee (2018 - Present): Member
- Yale Cancer Center Clinical Trial Office Search Committee (2018 - Present): Member
Publications
- Shimony S, Murdock H, Keating J, Tsai H, Sasi A, Gibson C, Faderl S, Wagner A, Dronamraju N, Lin T, Prebet T, Cortes J, Uy G, Lancet J, Reilly C, Neuberg D, Stone R, Lindsley R. CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial. Blood Advances 2026, 10: 2854-2864. PMID: 41628350, PMCID: PMC13133533, DOI: 10.1182/bloodadvances.2025019378.
- Voso M, de Botton S, Pfeilstöcker M, Alvarez A, Wang K, See W, Guerrero M, de Menezes D, Petrlik E, Prebet T, Roboz G. Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia‐related changes: Post hoc analysis of the QUAZAR AML‐001 trial. British Journal Of Haematology 2025, 208: 746-751. PMID: 41387169, DOI: 10.1111/bjh.70272.
- Boyiadzis M, Wei A, Paiva B, Freeman S, Kaspers G, Chyla B, Hersey S, Patel R, Maloney B, Zumofen M, Van Hoef M, Wulff B, Obourn V, Patel S, de Menezes D, Shi Q, Bengoudifa B, Dimier N, Prior T, Roboz G, Prebet T. Measurable residual disease (MRD) as a surrogate end point for clinical drug approval in acute myeloid leukemia (AML): Perspectives from the MRD Partnership and Alliance in AML Clinical Treatment Consortium. Cancer 2025, 131: e35960. PMID: 40576165, PMCID: PMC12203635, DOI: 10.1002/cncr.35960.
- Leber B, Ruiz M, Elgendy H, Pettersson F, Prebet T, Vigil C, Parikh R, Korgaonkar S, Bello F, Davis K, Gaugler L, Strocchia M, Sieluk J, Li Y, Schuh A. Real‐world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Cancer 2025, 131: e35845. PMID: 40233158, DOI: 10.1002/cncr.35845.
- Mims A, Xie Z, Potluri R, Rotter D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia. Leukemia & Lymphoma 2024, 66: 479-487. PMID: 39606887, DOI: 10.1080/10428194.2024.2425792.
- Poloni A, Raaschou-Jensen K, Mohedo F, Paolini S, Oliva E, Buccisano F, Vasconcelos A, Kim I, Makwana A, Bernasconi D, Rosettani B, Prebet T, Santini V. Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance Study. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e131-e142. PMID: 39516085, DOI: 10.1016/j.clml.2024.10.007.
- Borate U, Seiter K, Potluri R, Mazumder D, Chevli M, Prebet T, Gaugler L, Strocchia M, Vasconcelos A, Sieluk J. Healthcare Utilization and Costs Among Patients with Acute Myeloid Leukemia Receiving Oral Azacitidine Maintenance Therapy Versus No Maintenance: A US Claims Database Study. Advances In Therapy 2024, 41: 4049-4064. PMID: 39240504, PMCID: PMC11480148, DOI: 10.1007/s12325-024-02947-1.
- Della Porta M, Garcia-Manero G, Santini V, Zeidan A, Komrokji R, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T, Fenaux P, Platzbecker U. Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. The Lancet Haematology 2024, 11: e646-e658. PMID: 39038479, DOI: 10.1016/s2352-3026(24)00203-5.
- Montesinos P, Fathi A, de Botton S, Stein E, Zeidan A, Zhu Y, Prebet T, Vigil C, Bluemmert I, Yu X, DiNardo C. Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Advances 2024, 8: 2509-2519. PMID: 38507688, PMCID: PMC11131052, DOI: 10.1182/bloodadvances.2023011914.
- Risueño A, See W, Bluemmert I, de Botton S, DiNardo C, Fathi A, Schuh A, Montesinos P, Vyas P, Prebet T, Gandhi A, Hasan M. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leukemia Research 2024, 140: 107497. PMID: 38564986, DOI: 10.1016/j.leukres.2024.107497.
- Mims A, Xie Z, Vasconcelos A, Strocchia M, Heydendael W, Chevli M, Rotter D, Potluri R, Prebet T, Sieluk J. Corrigendum to “AML-068 - Survival Differences in Patients With Acute Myeloid Leukemia (AML) Treated With Oral Azacitidine (Oral-AZA) as Maintenance and Those Eligible but Not Treated in a US Electronic Health Record (EHR) Database” [Clinical Lymphoma, Myeloma & Leukemia, 23S1 (2023) S1-S593]. Clinical Lymphoma Myeloma & Leukemia 2024, 24: 203-204. DOI: 10.1016/j.clml.2023.11.010.
- Watts J, Baer M, Yang J, Prebet T, Lee S, Schiller G, Dinner S, Pigneux A, Montesinos P, Wang E, Seiter K, Wei A, De Botton S, Arnan M, Donnellan W, Schwarer A, Récher C, Jonas B, Ferrell P, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard S, Brevard J, Henrick P, Mohamed H, Cortes J. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. The Lancet Haematology 2022, 10: e46-e58. PMID: 36370742, PMCID: PMC12250719, DOI: 10.1016/s2352-3026(22)00292-7.
- Pollyea D, Bixby D, Perl A, Bhatt V, Altman J, Appelbaum F, de Lima M, Fathi A, Foran J, Gojo I, Hall A, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin M, Mims A, Neff J, Nejati R, Olin R, Percival M, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami P, Stone R, Strickland S, Sweet K, Vachhani P, Wieduwilt M, Gregory K, Ogba N, Tallman M. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 16-27. PMID: 33406488, DOI: 10.6004/jnccn.2021.0002.
- Tallman M, Wang E, Altman J, Appelbaum F, Bhatt V, Bixby D, Coutre S, De Lima M, Fathi A, Fiorella M, Foran J, Hall A, Jacoby M, Lancet J, LeBlanc T, Mannis G, Marcucci G, Martin M, Mims A, O'Donnell M, Olin R, Peker D, Perl A, Pollyea D, Pratz K, Prebet T, Ravandi F, Shami P, Stone R, Strickland S, Wieduwilt M, Gregory K, Hammond L, Ogba N. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 721-749. PMID: 31200351, DOI: 10.6004/jnccn.2019.0028.
- Fenaux G, Ades L, Fontenay M, Raynaud S, Eclache V, Rose C, Guerci-Bresler A, Gyan E, Robin M, Prebet T, Itzykson R, Cluzeau T, Natarajan-Amé S, Stamatoullas A, Wattel E, Park S, Beyne Rauzy O, Solary E, Bordessoule D, Isnard F, Quesnel B, Yakoub Agha I, Toma A, Thépot S, Braun T, Gardin C, Chèze S, Delaunay J, Dimicoli S, Kosmider O, Renneville A, Preudhomme C, Chermat F, Vey N, Dreyfus F. French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. Hématologie 2015, 21: 28-45. DOI: 10.1684/hma.2015.0979.
Departments and Programs
Locations
1
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
1 of 3
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- 37 College StreetNew Haven, CT 06510
1
Smilow Cancer Hospital
Smilow Cancer Hospital at Yale New Haven
35 Park Street
New Haven, CT 06511
1 of 3
- Smilow Cancer HospitalSmilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Yale New Haven Hospital20 York StreetNew Haven, CT 06510
- 37 College StreetNew Haven, CT 06510